Obese Americans turning to Ozempic clones
Over 40 percent of Americans suffer from obesity, reflecting a major health crisis and the massive market for new Ozempic-type drugs
Daily TribuneOver 40 percent of Americans suffer from obesity, reflecting a major health crisis and the massive market for new Ozempic-type drugs
WASHINGTON (AFP) — Like many Americans struggling to lose weight, Marissa Montanino felt compelled to try Ozempic or one of the other new so-called "wonder drugs" described as revolutionary in the fight against obesity.
"I would work out sometimes three times a day. I was doing hours worth of classes. I was eating really, really clean… and nothing was changing," the 36-year-old esthetician told AFP. "I heard about Ozempic for a while and then you start to see other people doing it like celebrities and then dropping weight super fast."
Ultimately deciding to take the leap, Montanino was not prescribed Ozempic, made by Danish drugmaker Novo Nordisk, but rather "compounded" semaglutide. It's an option many in the United States are turning to over cost or supply problems with brand name drugs — but which experts and officials have flagged for possible risks.
Over 40 percent of Americans suffer from obesity, reflecting a major health crisis and the massive market for new Ozempic-type drugs. With their "groundbreaking" effectiveness, the drugs will be "the first line therapy for people who are obese," research physician Samuel Klein of Washington University in St. Louis told AFP.
Semaglutide is the active ingredient in both Ozempic — approved as a diabetes treatment in 2017 — and Novo Nordisk's Wegovy, which gained authorization as an obesity medicine in 2021.
In addition to the millions of diabetic and obese patients seeking out the drugs, countless others without severe health issues are asking doctors for "off-label" prescriptions. Celebrities, including Elon Musk, have also said they take the drugs to shed pounds — fueling skyrocketing interest.
The US Food and Drug Administration classifies semaglutide and tirzepatide — the compound used by Eli Lilly in its drugs Mounjaro and Zepbound — as currently "in shortage." The designation means some restrictions may be lifted, allowing the compounding of drugs that are "essentially copies of approved drugs," the FDA says.